News about Safety

WHO Issues First Global Guideline on GLP-1 Therapies for Obesity

To tackle the growing global health challenge of obesity—which now affects more than one billion people worldwide—the World Health Organization (WHO) has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease.

Safety | 03/12/2025 | By Darshana |  152

Otsuka receives FDA accelerated approval for Voyxact in adults with IgA nephropathy

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the US FDA has granted accelerated approval for Voyxact (sibeprenlimab-szsi) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.

Safety | 27/11/2025 | By Darshana |  303

Union Health Minister Launches National Action Plan on Antimicrobial Resistance 2.0

Union Minister of Health and Family Welfare Jagat Prakash Nadda on Tuesday (18 November) launched the second version of the National Action Plan on Antimicrobial Resistance (NAP-AMR 2025–29), reinforcing India’s commitment to combating the growing threat of AMR.

Safety | 19/11/2025 | By Dineshwori |  124

WHO Issues Alert Over Contaminated Oral Liquid Medicines from India

The World Health Organization (WHO) has issued a Medical Product Alert following the identification of three substandard (contaminated) oral liquid medicines in India.

Safety | 14/10/2025 | By Dineshwori |  551

Aarti Drugs to Halt Chlorosulfonation Process at Tarapur Unit After Gas Leak

The Maharashtra Pollution Control Board (MPCB) has directed Aarti Drugs to voluntarily close down chlorosulfonation process at the PTSCL section of its T-150 unit in Tarapur as a precautionary and safety measure, following a gas leakage incident.

Safety | 10/09/2025 | By Dineshwori |  393

Dr Reddy's UK API Facility Receives Seven FDA Observations Following Inspection

Dr Reddy’s Laboratories has announced that its Active Pharmaceutical Ingredient (API) manufacturing facility in Mirfield, West Yorkshire, United Kingdom, has come under scrutiny from the United States Food and Drug Administration (FDA).

Safety | 08/09/2025 | By Darshana |  520

ASPA Calls for Unified, Multi-Stakeholder Approach to Combat Counterfeiting

Through evidence-based research, collaboration, and the adoption of authentication technologies, we can build a future where counterfeiting is no longer a silent threat, says Puneet Maithani, Director – Industry Affairs, ASPA.

Safety | 05/08/2025 | By Dineshwori |  400

Monitor NDMA Impurity in Ranitidine Formulation: DCGI Directs Indian Drugmakers

The DCGI has instructed drug controllers of all States and Union Territories to ensure that manufacturers under their jurisdiction monitor the presence of N-Nitrosodimethylamine(NDMA) - a potentially carcinogenic impurity – in the active pharmaceutical ingredient (API) and formulation of the antacid Ranitidine.

Safety | 31/07/2025 | By Dineshwori |  1087

Sarepta Pauses Shipments of Duchenne Gene Therapy Elevidys Amid FDA Safety Review

Sarepta Therapeutics has announced a voluntary and temporary suspension of all US shipments of its Duchenne muscular dystrophy (DMD) gene therapy, ELEVIDYS (delandistrogene moxeparvovec), following the FDA’s distribution suspension request last week.

Safety | 24/07/2025 | By Dineshwori |  432

Custom Portable Sampling Isolator Improves Safety of Pharmaceutical Manufacturing

Custom Portable Sampling Isolator Improves Safety of Pharmaceutical Manufacturing

Safety | 18/08/2023 | By Sudeep Soparkar |  1053